GURUFOCUS.COM » STOCK LIST » USA » NAS » Keros Therapeutics Inc (NAS:KROS) » Definitions » Profitability Rank
Switch to:

Keros Therapeutics (NAS:KROS) Profitability Rank

: 1 (As of Jun. 2023)
View and export this data going back to 2020. Start your Free Trial

Keros Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Keros Therapeutics's Operating Margin % for the quarter that ended in Jun. 2023 was %. As of today, Keros Therapeutics's Piotroski F-Score is 2.


Competitive Comparison

For the Biotechnology subindustry, Keros Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Keros Therapeutics Profitability Rank Distribution

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's Profitability Rank falls in comparison to its industry or sector. The grey bar indicates the Profitability Rank's extreme value range as defined by GuruFocus.



Keros Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Keros Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Keros Therapeutics's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-41.337 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Keros Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Keros Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Keros Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Keros Therapeutics (NAS:KROS) Business Description

Keros Therapeutics logo
Traded in Other Exchanges
N/A
Address
1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Executives
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Christopher Rovaldi officer: Chief Operating Officer C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139
Simon Peter Cooper officer: Chief Medical Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Pontifax Late Stage Fund L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 L3 46140
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jennifer Lachey officer: Chief Scientific Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Claudia Ordonez officer: Chief Medical Officer C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Julius Knowles director C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Arkin Bio Venture Partners Ltd. 10 percent owner 6 HACHOSHLIM STREET, BUILDING C, HERZLIYA PITUACH L3 4672406
Arkin Bio Ventures Limited Partnership 10 percent owner 6 HACHOSHLIM STREET, HERZLIYA PITUACH L3 4672406
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Moshe Arkin 10 percent owner 6 HACHOSHLIM ST., HERZELIA L3 4672406
Nima Farzan director C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Pontifax Late Stage Gp Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 L3 46140

Keros Therapeutics (NAS:KROS) Headlines

From GuruFocus